Routine Clinical Adoption of Pharmacogenomic Testing Poised for Gradual Expansion Outside of Oncology

摘要

Researchers are optimistic that pharmacogenomic (PGx) testing will make gradual inroads into clinical practice over the next five years, but they say the most notable progress will be in disciplines outside of oncology. Clini-cal utilization of PGx testing will be propelled by institutional efforts to make health care more cost-effective while improving patient outcomes through personalized medicine.